Debut Plus

₹828.7

▼ -21.86 -2.57%

17 Jul 2026

NSE Listed · Pharmaceuticals

Supriya Lifescience Ltd. (SUPRIYA)

Volume: 1,62,479Avg Vol 1W: 83,187Avg Vol 1M: 2,78,96752W Range:₹545.5₹1,085
NSE BSE www.supriyalifescience.com
Key Ratios
Checked 8h ago
Market Cap₹6,677 Cr
Current Price₹828.7
Previous Close₹850.56
High / Low (52w)₹1,085 / ₹545.5
Volume1,62,479
Avg Vol (1W)83,187
Avg Vol (1M)2,78,967
Stock P/E31.87
Book Value₹148.82
Dividend Yield12%
ROE17.46%
ROA15.41%
Revenue (TTM)₹828 Cr
Revenue Growth—
Profit Margin25.26%
Total Debt—
Shares Outstanding8 Cr
Face Value₹2
EPS (TTM)₹26.03
P/B5.57
Debt / Equity0.01
50 DMA₹918.02
200 DMA₹749.43
Day change-2.57%
Price Chart
₹828.7▲ 9.47% · 1Y
₹1053₹55158.0L
2025-11-25
2026-07-17

20-day avg volume: 3.0L shares

Pros
  • Healthy return on equity of 17.5%.
  • Pays a dividend yield of 12.0%.
  • Company is almost debt-free.
  • Revenue grew 1172129307% YoY.
  • Net profit is growing year over year.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹161 Cr₹166 Cr₹186 Cr₹184 Cr₹145 Cr₹200 Cr₹206 Cr₹277 Cr
EBITDA₹60 Cr₹62 Cr₹63 Cr₹64 Cr₹48 Cr₹69 Cr₹68 Cr₹93 Cr
Net Profit₹45 Cr₹46 Cr₹47 Cr₹50 Cr₹35 Cr₹50 Cr₹50 Cr₹74 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue₹286 Cr₹323 Cr₹396 Cr₹538 Cr₹470 Cr₹581 Cr₹706 Cr₹828 Cr
EBITDA₹67 Cr₹103 Cr₹171 Cr₹211 Cr₹127 Cr₹168 Cr₹250 Cr₹0 Cr
Net Profit₹39 Cr₹73 Cr₹124 Cr₹152 Cr₹90 Cr₹119 Cr₹188 Cr₹209 Cr
EPS5.3910.0216.8918.8611.1614.823.35—
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹253 Cr₹336 Cr₹445 Cr₹735 Cr₹820 Cr₹921 Cr₹1,112 Cr₹1,357 Cr
Total Liabilities₹159 Cr₹187 Cr₹177 Cr₹119 Cr₹121 Cr₹106 Cr₹116 Cr₹159 Cr
Equity₹94 Cr₹149 Cr₹269 Cr₹616 Cr₹699 Cr₹815 Cr₹997 Cr₹1,198 Cr
Total Debt———————₹5 Cr
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹106 Cr₹110 Cr₹94 Cr₹151 Cr₹224 Cr₹186 Cr
Investing₹-47 Cr₹-60 Cr₹-124 Cr₹-174 Cr₹-152 Cr₹-176 Cr
Financing₹-15 Cr₹150 Cr₹-10 Cr₹-22 Cr₹-8 Cr₹-10 Cr
Free Cash Flow₹106 Cr₹110 Cr₹94 Cr₹151 Cr₹224 Cr₹34 Cr
Shareholding
Promoter 68.3% Institutions 10.86% Public 20.84%
About Supriya Lifescience Ltd.

Pharmaceuticals · Pharmaceuticals - Indian - Bulk Drugs & Formln

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.

www.supriyalifescience.com ↗
Efficiency & Working Capital
ROCE23%
Interest Coverage138.3
Dividend Payout—
Debtor Days63 d
Inventory Days55 d
Payable Days35 d
Cash Conversion Cycle83 d
Working Capital Days118 d
Shareholding Details

As of 2026-03-31

Promoter68.3%
FII5.2%
DII5.7%
Institutions10.9%
Public20.8%
Promoter Pledge0%
No. of Shareholders81,161
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodJun 2023Sept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Promoters68.3%68.3%68.3%68.3%68.3%68.3%68.3%68.3%68.3%68.3%68.3%68.3%
FIIs5.7%5.3%4.6%5.4%4.9%6%6.5%7.2%6.8%5.5%5.2%5.2%
DIIs7.5%7.2%3.8%5.3%5.5%5.4%4.9%4.3%4.9%5.2%5%5.7%
Public18.4%19.2%23.3%21%21.3%20.2%20.3%20.3%20.1%21%21.5%20.8%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders93,47892,99195,92987,98089,62185,32889,39491,05191,92887,91285,09981,161
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503————
Major Shareholders (>1%)
NameCategoryStakeShares
Satish Waman WaghShareholding of Promoter and Promoter Group67.6%5.44 Cr
Cohesion Mk Best Ideas Sub-trustPublic Shareholding3%24,01,769
Aditya Birla Sun Life Insurance Company LimitedPublic Shareholding2.1%17,21,030
Smita Satish WaghShareholding of Promoter and Promoter Group0.4%3,21,750
Saloni Satish WaghShareholding of Promoter and Promoter Group0.1%1,02,375
Shivani Satish WaghShareholding of Promoter and Promoter Group0.1%1,02,375
Arun Waman WaghShareholding of Promoter and Promoter Group0%110
Satish Waman Wagh Partner Representing SupriyapharmaceuticalsShareholding of Promoter and Promoter Group0%10
Promoter Pledges
HolderPledged Shares% of HoldingAs of
Satish Waman Wagh00%2026-03-31
Smita Satish Wagh00%2026-03-31
Saloni Satish Wagh00%2026-03-31
Shivani Satish Wagh00%2026-03-31
Arun Waman Wagh00%2026-03-31
Satish Waman Wagh Partner Representing Supriyapharmaceuticals00%2026-03-31
Aditya Birla Sun Life Insurance Company Limited00%2026-03-31
Cohesion Mk Best Ideas Sub-trust00%2026-03-31
Satish Waman Wagh00%2025-12-31
Smita Satish Wagh00%2025-12-31
Saloni Satish Wagh00%2025-12-31
Shivani Satish Wagh00%2025-12-31
Board of Directors
NameDesignationYear
Satish Waman WaghChairman / Executive Director / Managing Director2025
Smita Satish WaghE D & Wholetime Director2025
Saloni Satish WaghE D & Wholetime Director2025
Shivani Satish WaghE D & Wholetime Director2025
Balasaheb G. SawantE D & Wholetime Director2025
Neelam Yashpal AroraIndependent Non Exe. Director2025
Ganapati D YadavIndependent Non Exe. Director2025
Sunil Subhash BhagwatIndependent Non Exe. Director2025
Prachi SatheCompany Sec. & Compli. Officer2025
MANISH ISHWARLAL PANCHALAdditional Independent Director2025
Kothandaraman HariAdditional Independent Director2025
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹2351616
Corporate Actions
TypeDateValueRemark
dividend2025-09-04₹1 (50%)Final
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
202500032234
2025000101
202500031234
Insider / Designated-Person Trades

8 recent disclosure(s)

Shivani Satish WaghAcquisition · 73,125
Saloni Satish WaghDisposal · 73,125
Satish Waman WaghAcquisition · 13,000
Satish Waman WaghAcquisition · 14,000
Satish Waman WaghAcquisition · 2,000
Satish Waman WaghAcquisition · 8,000
Substantial Acquisitions (SAST)

6 disclosure(s)

-26/02/2024 · 73,125
Off Market / Inter se transfer26/02/2024 · 73,125
Off Market / Inter se transfer26/02/2024 · 73,125
Off Market / Inter se transfer26/02/2024 · 73,125
Off Market / Inter se transfer26/02/2024 · 73,125
NULL27/12/2023 · 73,125
Company Information
Incorporated2008
ChairmanSatish Waman Wagh
AuditorKakaria & Associates LLP
Investor Email[email protected]
🌐 www.supriyalifescience.com ↗

📍 207/208 Udyog Bhavan, Sonawala Road Goregaon (East), Mumbai, Maharashtra, 400063

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Suprajit Engineering Ltd.Supreme Holdin N Hosp I LimitedSupreme Engineering Ltd.Supreme Industries Ltd.Supreme Infra. Ltd.Supreme Power Equipment LimitedSuraj Estate Developers LimitedSuraj LimitedSuraksha Diagnostic Ltd.Surana Solar LimitedSurana Telecom And Pow Ltd.Surani Steel Tubes Ltd.All “S” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search